View in EDS

A scoping review about the efficacy of clonazepam for the treatment of benign essential blepharospasm.

Saved in:
Bibliographic Details
Title: A scoping review about the efficacy of clonazepam for the treatment of benign essential blepharospasm.
Authors: Torrente, Angelo (AUTHOR), Alonge, Paolo (AUTHOR), Pignolo, Antonia (AUTHOR), Lo Mauro, Eloise (AUTHOR), Monastero, Roberto (AUTHOR), Labate, Angelo (AUTHOR)
Source: Neurological Sciences. Jul2026, Vol. 47 Issue 7, p1-6. 6p.
Abstract: Background: Benign Essential Blepharospasm (BEB) is a focal dystonia that leads to an increased rate of eyelid closure due to involuntary activation of the orbicularis oculi muscles. In severe cases, daily activities can significantly be affected, with reduced quality of life. Injections of OnabotulinumtoxinA are often used as valid therapeutical option. However, this treatment may not be tolerated by all patients, considering its invasive nature and the need for access to specialized centers. Despite oral agents, such as benzodiazepines (particularly clonazepam), are often used as a first-line treatment, evidence regarding their efficacy remains fragmentary. Objective: This scoping review aims to evaluate the current evidence for the efficacy of clonazepam for benign essential blepharospasm. Methods: Articles in English about the use of clonazepam in the treatment of BEB were searched for in three major databases (PubMed, Scopus, Cochrane). Results: The search yielded 259 results. After screening, 13 papers were sought for retrieval. After assessing their suitability, 2 articles were included in the review: one open-label trial and one case report. Despite some limitations, both showed the effectiveness of clonazepam in BEB. Conclusion: Although some evidence supports the use of clonazepam in the treatment of BEB, high-quality studies are still needed to clarify aspects such as response rates, optimal dose, and other disease management issues. This information may be useful for clinicians who are unable to refer their patients to specialized centers and must rely on their own experience and anecdotal evidence for patient management. [ABSTRACT FROM AUTHOR]
Copyright of Neurological Sciences is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Description
Abstract:Background: Benign Essential Blepharospasm (BEB) is a focal dystonia that leads to an increased rate of eyelid closure due to involuntary activation of the orbicularis oculi muscles. In severe cases, daily activities can significantly be affected, with reduced quality of life. Injections of OnabotulinumtoxinA are often used as valid therapeutical option. However, this treatment may not be tolerated by all patients, considering its invasive nature and the need for access to specialized centers. Despite oral agents, such as benzodiazepines (particularly clonazepam), are often used as a first-line treatment, evidence regarding their efficacy remains fragmentary. Objective: This scoping review aims to evaluate the current evidence for the efficacy of clonazepam for benign essential blepharospasm. Methods: Articles in English about the use of clonazepam in the treatment of BEB were searched for in three major databases (PubMed, Scopus, Cochrane). Results: The search yielded 259 results. After screening, 13 papers were sought for retrieval. After assessing their suitability, 2 articles were included in the review: one open-label trial and one case report. Despite some limitations, both showed the effectiveness of clonazepam in BEB. Conclusion: Although some evidence supports the use of clonazepam in the treatment of BEB, high-quality studies are still needed to clarify aspects such as response rates, optimal dose, and other disease management issues. This information may be useful for clinicians who are unable to refer their patients to specialized centers and must rely on their own experience and anecdotal evidence for patient management. [ABSTRACT FROM AUTHOR]
ISSN:15901874
DOI:10.1007/s10072-026-09172-4